How should I evaluate and manage a 48-year-old obese female with hypertension (BP 150/100 mmHg) who has a 3-year history of symmetric polyarticular pain and morning stiffness involving the knees, ankles, wrists, and shoulders, and a prior chikungunya infection?

Approach to Polyarticular Arthritis with Post-Chikungunya Syndrome and Hypertension

This patient requires urgent rheumatology referral within 6 weeks to evaluate for inflammatory arthritis (likely post-chikungunya chronic arthropathy versus rheumatoid arthritis), immediate initiation of blood pressure control with RAS inhibitors, and weight reduction targeting her obesity (BMI 34.7 kg/m²). 1, 2

Immediate Diagnostic Workup

Clinical Assessment

• Document joint examination findings: Look specifically for symmetric synovitis (joint swelling with warmth), tender joint count, and swollen joint count in the bilateral knees, ankles, wrists, and shoulders 1
• Quantify morning stiffness duration: >1 hour suggests inflammatory arthritis rather than osteoarthritis 3
• Assess for systemic features: Rashes, oral ulcers, fever, or other organ involvement to differentiate inflammatory causes 3

Essential Laboratory Tests

Order the following to distinguish post-chikungunya chronic arthropathy from rheumatoid arthritis:

• Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA): Critical for diagnosing RA 1
• Acute phase reactants: ESR and CRP to confirm inflammation 1
• Complete metabolic panel: Baseline renal and hepatic function before DMARD initiation
• Fasting glucose and HbA1c: Given her obesity and hypertension, screen for diabetes 4
• Lipid panel: Inflammatory arthritis increases cardiovascular risk 2

Imaging

• Ultrasonography of affected joints: Confirms synovitis when clinical examination is equivocal 1
• Baseline radiographs: Document erosive changes if present 1

Diagnostic Considerations

Post-Chikungunya Chronic Arthropathy vs. Rheumatoid Arthritis

This is the critical diagnostic dilemma. The patient has:

• Symmetric polyarticular involvement with morning stiffness: Classic for both conditions
• 3-year duration: 15-60% of chikungunya patients develop chronic polyarthralgia lasting months to years 5
• Prior chikungunya infection: Temporal relationship suggests post-viral arthropathy

However, if RF/ACPA are positive with elevated inflammatory markers and erosive changes on imaging, this represents true RA that may have been triggered or unmasked by chikungunya infection 1, 6.

Treatment Strategy

For Inflammatory Arthritis Management

If RF/ACPA positive or high-risk features present (multiple swollen joints, elevated CRP/ESR, erosions):

• Start methotrexate immediately (within 3 months of presentation, ideally sooner) as the anchor DMARD, even if classification criteria for RA are not fully met 1
• Dose: 15-25 mg weekly with folic acid supplementation
• Contraindications to check: Liver disease, renal impairment, pregnancy potential

Symptomatic management while awaiting DMARD effect:

• Short-term systemic glucocorticoids: Prednisone 10-15 mg daily for <6 months to bridge until DMARD efficacy 1
• Intra-articular glucocorticoid injections: For severely affected individual joints 1
• NSAIDs: Use minimum effective dose for shortest duration after evaluating her cardiovascular (hypertension), renal, and gastrointestinal risks 1

Treatment target: Clinical remission assessed monthly using composite measures (DAS28, CDAI) until target achieved 1

For Hypertension Management

Her BP 150/100 mmHg requires immediate treatment:

• First-line: RAS inhibitor (ACE inhibitor or ARB): Specifically recommended for inflammatory rheumatic diseases due to overactive renin-angiotensin-aldosterone system 2
• Add calcium channel blocker (CCB) if BP remains >140/90 mmHg on monotherapy 2
• Target BP <130/80 mmHg given her multiple cardiovascular risk factors (obesity, possible metabolic syndrome) 2, 7

Avoid or use cautiously:

• NSAIDs will worsen BP control and should be minimized 2
• Monitor for drug interactions between antihypertensives and DMARDs

For Obesity Management (BMI 34.7 kg/m²)

Weight reduction is critical as it:

• Improves BP control 8
• Reduces mechanical stress on weight-bearing joints (knees, ankles)
• Decreases cardiovascular risk in inflammatory arthritis 2

Target: 5-10% weight loss through dietary modification and exercise

Monitoring Protocol

Disease Activity Monitoring

• Monthly visits until remission achieved: Assess tender/swollen joint counts, patient/physician global assessment, ESR/CRP 1
• Every 3 months once stable: Continue composite disease activity measures
• Radiographs annually: Monitor for progressive erosive disease 1

Safety Monitoring on Methotrexate

• Baseline: CBC, comprehensive metabolic panel, hepatitis B/C screening
• Every 4-8 weeks: CBC, liver enzymes, creatinine
• Watch for: Cytopenias, hepatotoxicity, pulmonary toxicity

Cardiovascular Risk Management

Given inflammatory arthritis increases cardiovascular risk by one step 2:

• Statin therapy: If LDL-C >100 mg/dL (2.6 mmol/L) for primary prevention 2
• Fasting glucose <126 mg/dL or HbA1c <7% if diabetes develops 2
• Aggressive BP control as outlined above

Critical Pitfalls to Avoid

1. Delaying rheumatology referral: Patients under rheumatologist care have better outcomes with earlier diagnosis and treatment 1
2. Attributing all symptoms to post-chikungunya arthropathy: Missing concurrent RA leads to untreated erosive disease 6
3. Prolonged NSAID use: Worsens hypertension and increases cardiovascular risk in this high-risk patient 1, 2
4. Ignoring cardiovascular risk: Inflammatory arthritis plus hypertension plus obesity creates substantial CVD risk requiring aggressive management 2, 4
5. Inadequate monitoring: Monthly assessment is essential until remission to adjust therapy and prevent joint damage 1